Erythropoietin

HONOLULU — Erythropoietin did not reduce the risk for death or severe disability among infants with hypoxic ischemic encephalopathy already being treated with hypothermia, according to the results of a phase 3 randomized controlled trial.

Pediatric patients with anemia and chronic kidney disease can alternate between maintenance erythropoiesis-stimulating agents and subcutaneous continuous erythropoietin receptor activators every 4 weeks, according to a study.

High-dose erythropoietin failed to lower the risk for death among newborns undergoing therapeutic hypothermia for neonatal hypoxic ischemic encephalopathy, according to study findings published in The New England Journal of Medicine.

Three scientists — two from the United States and one from England — the Nobel Prize in Medicine or Physiology for their discoveries of how cells sense and adapt to oxygen availability.